Sigyn Therapeutics (OTCMKTS:SIGY – Get Free Report) and Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.
Profitability
This table compares Sigyn Therapeutics and Vivos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sigyn Therapeutics | N/A | N/A | -820.79% |
| Vivos Therapeutics | -124.52% | -256.45% | -127.14% |
Risk & Volatility
Sigyn Therapeutics has a beta of -1.33, suggesting that its share price is 233% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 2.62, suggesting that its share price is 162% more volatile than the S&P 500.
Institutional & Insider Ownership
Analyst Recommendations
This is a summary of current recommendations and price targets for Sigyn Therapeutics and Vivos Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sigyn Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Vivos Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Earnings and Valuation
This table compares Sigyn Therapeutics and Vivos Therapeutics’ top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sigyn Therapeutics | N/A | N/A | -$2.93 million | ($0.09) | -1.67 |
| Vivos Therapeutics | $16.24 million | 0.63 | -$23.84 million | ($0.86) | -0.40 |
Sigyn Therapeutics has higher earnings, but lower revenue than Vivos Therapeutics. Sigyn Therapeutics is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Vivos Therapeutics beats Sigyn Therapeutics on 6 of the 11 factors compared between the two stocks.
About Sigyn Therapeutics
Sigyn Therapeutics, Inc. operates as a medical technology company, focuses on creating therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. It also developing ChemoPrep to enhance the tumor site delivery of chemotherapy; and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis. The company is headquartered in San Diego, California.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.
Receive News & Ratings for Sigyn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigyn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
